Join this webinar to discover the advantages of using Signatera™ (RUO), a novel assay custom-designed for each patient that detects circulating tumor DNA (ctDNA) with high sensitivity and specificity to monitor molecular residual disease, early recurrence, and treatment response across solid tumors.
To help improve the understanding of the immune system, as well as the therapies being developed to manipulate it, the National Institutes of Health is funding a major study in pet dogs that have naturally occurring tumors.
Colorado State University’s Flint Animal Cancer Center has long been a proponent of a worldwide effort to recruit dogs that develop cancer into clinical trials that could translate to new therapies for people. Now the university’s veterinarians will be able to preach the value of their research to a broad audience with a new PBS documentary.
Scientists at Ontario Veterinary College (OVC) at the University of Guelph have discovered that injecting a cancer-killing virus into the spleens of cats who have developed cancer boosts the animals’ immune response to the disease.